To circumvent the limitations associated with the expansion of HER-2/neu+ tumour-specific T cells, we have adopted an approach in which T lymphocytes are grafted with a permanent antibody-dictated specificity (Eshhar et al, 2001). This evidence concerns the gene ERBB2 and neoplasm.